Pediatric Intensive Care: Immunomodulation With Activated Protein C ex vivo

• Egile Nagusiak: Hassan O. Eliwan (Egilea), William R. G. Watson (Egilea), Irene Regan (Egilea), Brian Philbin (Egilea), Fiona M. O'Hare (Egilea), Tammy Strickland (Egilea), Amanda O'Neill (Egilea), Michelle O'Rourke (Egilea), Alfonso Blanco (Egilea), Martina Healy (Egilea), Beatrice Nolan (Egilea), Owen Smith (Egilea), Eleanor J. Molloy (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2019-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Sepsis is major cause of morbidity and mortality in the Pediatric Intensive Care Unit (PICU). PICU patients may develop transient immune deficiency during sepsis. Activated Protein C (APC) has significant anti-inflammatory and cytoprotective effects. Clinical trials of APC in adult sepsis...